Abo Bibliothek: Guest
Critical Reviews™ in Oncogenesis

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma

Volumen 23, Ausgabe 3-4, 2018, pp. 219-234
DOI: 10.1615/CritRevOncog.2018027528
Get accessGet access

ABSTRAKT

Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is one of the most common head and neck malignancies in southern China and Southeast Asia. Unfortunately, 70% of NPC patients have locally advanced disease at the first diagnosis. Radiotherapy alone and concurrent chemoradiotherapy are important treatment approaches for NPC, but they have a limited effect on patients with locally advanced or distantly metastatic disease. 1–5 Nevertheless, the unique immune environment of the EBV-associated NPC provides rational targets for immunotherapy. Diverse types of immunotherapies are actively being studied, including adoptive immunotherapy, therapeutic vaccines, immune checkpoint inhibitors, lytic-induction therapy, and viral immunotherapy. Specifically, adoptive immunotherapy with lymphocyte infusion was well tolerated and effective in 71.4% of patients combined with first-line chemotherapy. Several therapeutic vaccines and PD-1/PD-L1 pathway checkpoint inhibitors have shown promising clinic outcomes at phase I/II clinical trials. Moreover, EBV-lytic inducing therapy and viral immunotherapy for NPC are also being investigated. In this review, we summarized the current status, advantages, and disadvantages of each immunotherapy for EBV-associated NPC, which may shed light on developing safer and more effective treatment modalities in the future.

REFERENZIERT VON
  1. van Zyl Dwain G., Mautner Josef, Delecluse Henri-Jacques, Progress in EBV Vaccines, Frontiers in Oncology, 9, 2019. Crossref

  2. Gao Peipei, Lazare Cordelle, Cao Canhui, Meng Yifan, Wu Ping, Zhi Wenhua, Lin Shitong, Wei Juncheng, Huang Xiaoyuan, Xi Ling, Chen Gang, Hu Junbo, Ma Ding, Wu Peng, Immune checkpoint inhibitors in the treatment of virus-associated cancers, Journal of Hematology & Oncology, 12, 1, 2019. Crossref

  3. Jouin Anaïs, Helfre Sylvie, Bolle Stéphanie, Claude Line, Laprie Anne, Bogart Emilie, Vigneron Céline, Potet Hélène, Ducassou Anne, Claren Audrey, Riet François Georges, Castex Marie Pierre, Faure-Conter Cécile, Fresneau Brice, Defachelles Anne Sophie, Orbach Daniel, Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience, Strahlentherapie und Onkologie, 195, 6, 2019. Crossref

  4. Leth Steffen, Jensen‐Fangel Søren, Programmed cell death protein 1 (PD‐1) in infection, APMIS, 128, 2, 2020. Crossref

  5. Zhang Xixia, Yang Jing, Shi Dong, Cao Zhiwei, TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism, Cancer Cell International, 20, 1, 2020. Crossref

  6. Tao Dan, Zhang Ningning, Huang Qingqing, Ge Chuang, Li Qicheng, Li Shujie, Weng Kegui, Guo Qishuai, Sui Jiangdong, Wang Can, Zhang Xin, Wang Ying, Association of Epstein-Barr virus infection with peripheral immune parameters and clinical outcome in advanced nasopharyngeal carcinoma, Scientific Reports, 10, 1, 2020. Crossref

  7. Olivares-Hernández Alejandro, Figuero-Pérez Luis, Miramontes-González José Pablo, López-Gutiérrez Álvaro, González-Sarmiento Rogelio, Cruz-Hernández Juan Jesús, Fonseca-Sánchez Emilio, Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors, Life, 11, 12, 2021. Crossref

  8. Chen Hao, Wei Lining, Luo Min, Wang Xiaochen, Zhu Chaohua, Huang Huixian, Liu Xu, Lu Heming, Zhong Yahua, LINC00324 suppresses apoptosis and autophagy in nasopharyngeal carcinoma through upregulation of PAD4 and activation of the PI3K/AKT signaling pathway, Cell Biology and Toxicology, 2021. Crossref

  9. Li Xiaoxu, Zhang Wenling, Expression of PD-L1 in EBV-associated malignancies, International Immunopharmacology, 95, 2021. Crossref

  10. Huang Wei, Song Wei, Jiang Yunfei, Chen Lejun, Lu Hong, c‐Myc‐induced circ‐NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the miR‐34c‐5p/c‐Myc axis, Cell Biology International, 45, 7, 2021. Crossref

  11. Gao Ying, Liu Zhe, Liu Yiting, Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects, World Journal of Surgical Oncology, 19, 1, 2021. Crossref

  12. Chua Tzy Harn, Punjabi Lavisha S, Khor Li Yan, Tissue Pathogens and Cancers: A Review of Commonly Seen Manifestations in Histo- and Cytopathology, Pathogens, 10, 11, 2021. Crossref

  13. Bian Jin, Niu Yan, Ma Yanli, Chen Fuhua, Ma Ning, Algalil Fahd Abd, A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy, Applied Bionics and Biomechanics, 2022, 2022. Crossref

  14. Zhu Jing, Fang Ruhua, Pan Zhiwen, Qian Xu, Circulating lymphocyte subsets are prognostic factors in patients with nasopharyngeal carcinoma, BMC Cancer, 22, 1, 2022. Crossref

  15. Liu Zijian, He Jinlan, Han Jiaqi, Yang Jiangping, Liao Wenjun, Chen Nianyong, m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma, Frontiers in Immunology, 12, 2022. Crossref

  16. Jiang Danxian, Li Yin, Cao Jinxin, Sheng Lianghe, Zhu Xinhai, Xu Meng, Cell Division Cycle-Associated Genes Are Potential Immune Regulators in Nasopharyngeal Carcinoma, Frontiers in Oncology, 12, 2022. Crossref

  17. Song Yexun, Cheng Wenwei, Li Heqing, Liu Xiajing, The global, regional, national burden of nasopharyngeal cancer and its attributable risk factors (1990–2019) and predictions to 2035, Cancer Medicine, 2022. Crossref

  18. Sun Xiuying, Zhou Jinhui, Zhang Zhicun, Cullin 4A/protein arginine methyltransferase 5 (CUL4A/PRMT5) promotes cell malignant phenotypes and tumor growth in nasopharyngeal carcinoma, Bioengineered, 13, 4, 2022. Crossref

  19. Takenaka Yukinori, Takemoto Norihiko, Otsuka Tomoyuki, Nishio Minako, Tanida Masashi, Fujii Takashi, Hayashi Kazuki, Suzuki Motoyuki, Mori Masashi, Yamamoto Yoshifumi, Uno Atsuhiko, Inohara Hidenori, Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: A multicenter retrospective study, Oral Oncology, 132, 2022. Crossref

  20. Ling Junjun, Zhang Liang, Chang Aoshuang, Huang Yi, Ren Jie, Zhao Houyu, Zhuo Xianlu, Overexpression of KITLG predicts unfavorable clinical outcomes and promotes lymph node metastasis via the JAK/STAT pathway in nasopharyngeal carcinoma, Laboratory Investigation, 2022. Crossref

  21. Zhong Qiong, Wang Zongqi, Kang Hualong, Wu Renrui, Molecular mechanism of FBXW7-mediated ubiquitination modification in nasopharyngeal carcinoma cell proliferation in vitro and in vivo, Pathology - Research and Practice, 2022. Crossref

  22. Liu Zijian, He Jinlan, Hu Xiaolin, Ferroptosis regulators related scoring system by Gaussian finite mixture model to predict prognosis and immunotherapy efficacy in nasopharyngeal carcinoma, Frontiers in Genetics, 13, 2022. Crossref

  23. Jiromaru Rina, Nakagawa Takashi, Yasumatsu Ryuji, Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options, Cancer Management and Research, Volume 14, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain